Skip to main content
Erschienen in: Diseases of the Colon & Rectum 11/2006

01.11.2006

Combined Measurement of Hepatocyte Growth Factor and Carcinoembryonic Antigen as a Prognostic Marker for Patients with Dukes A and B Colorectal Cancer: Results of a Five-Year Study

verfasst von: Chikao Miki, M.D., Yasuhiro Inoue, M.D., Jun-ichiro Hiro, M.D., Eiki Ojima, M.D., Toshimitsu Araki, M.D., Keiichi Uchida, M.D., Masato Kusunoki, M.D.

Erschienen in: Diseases of the Colon & Rectum | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Purpose

There is no marker capable of differentiating patients with Dukes A and B colorectal cancer with aggressive diseases from those with indolent diseases. We evaluated the results of five years of actuarial survival data to determine whether serial monitoring of serum hepatocyte growth factor could provide prognostic information on these patients.

Methods

Blood samples of 147 colorectal cancer patients were obtained and the serum concentration of hepatocyte growth factor was measured.

Results

Elevated serum hepatocyte growth factor levels were associated with stage progression. Although the overall positive rate of hepatocyte growth factor in the patients was the same as that of the carcinoembryonic antigen, the positive rate of hepatocyte growth factor in the Dukes A patients was two times higher than that of the carcinoembryonic antigen, and nearly 40 percent of the carcinoembryonic antigen-negative patients had a positive serum hepatocyte growth factor in the Dukes A and B classification. In this subgroup, patients with positive serum hepatocyte growth factor or carcinoembryonic antigen levels had a poorer prognosis, whereas positive serum hepatocyte growth factor level after surgery could predict disease recurrence.

Conclusions

A combination of serum hepatocyte growth factor and carcinoembryonic antigen tests might be useful for selecting patients with aggressive diseases in Dukes A and B classification.
Literatur
1.
Zurück zum Zitat Wein, A, Hahn, EG, Merkel, S, Hohenberger, W 2000Adjuvant chemotherapy for stage II colon cancerEur J Surg Oncol26730732PubMedCrossRef Wein, A, Hahn, EG, Merkel, S, Hohenberger, W 2000Adjuvant chemotherapy for stage II colon cancerEur J Surg Oncol26730732PubMedCrossRef
2.
Zurück zum Zitat Duffy, MJ 2001Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?Clin Chem47624630PubMed Duffy, MJ 2001Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?Clin Chem47624630PubMed
3.
Zurück zum Zitat Gold, P, Freedman, SO 1965Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniquesJ Exp Med121439462PubMedCrossRef Gold, P, Freedman, SO 1965Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniquesJ Exp Med121439462PubMedCrossRef
4.
Zurück zum Zitat Gold, P, Freedman, SO 1965Specific carcinoembryonic antigens of the human digestive systemJ Exp Med122467481PubMedCrossRef Gold, P, Freedman, SO 1965Specific carcinoembryonic antigens of the human digestive systemJ Exp Med122467481PubMedCrossRef
5.
Zurück zum Zitat Compton, CC, Fielding, LP, Burgart, LJ, et al. 2000Prognostic factors in colorectal cancerArch Pathol Lab Med124979994PubMed Compton, CC, Fielding, LP, Burgart, LJ,  et al. 2000Prognostic factors in colorectal cancerArch Pathol Lab Med124979994PubMed
6.
Zurück zum Zitat Moertel, CG, Fleming, TR, Macdonald, JS, Haller, DG, Laurie, JA, Tangen, C 1993An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancerJAMA270943947PubMedCrossRef Moertel, CG, Fleming, TR, Macdonald, JS, Haller, DG, Laurie, JA, Tangen, C 1993An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancerJAMA270943947PubMedCrossRef
7.
Zurück zum Zitat Nakamura, T, Nawa, K, Ichihara, A, Kaise, N, Nishino, T 1987Purification and subunit structure of hepatocyte growth factor from rat plateletsFEBS Lett224311316PubMedCrossRef Nakamura, T, Nawa, K, Ichihara, A, Kaise, N, Nishino, T 1987Purification and subunit structure of hepatocyte growth factor from rat plateletsFEBS Lett224311316PubMedCrossRef
8.
Zurück zum Zitat Gohda, E, Tsubouchi, H, Nakayama, H, et al. 1988Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failureJ Clin Invest81414419PubMedCrossRef Gohda, E, Tsubouchi, H, Nakayama, H,  et al. 1988Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failureJ Clin Invest81414419PubMedCrossRef
9.
Zurück zum Zitat Zarnegar, R, Michalopoulos, G 1989Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytesCancer Res4933143320PubMed Zarnegar, R, Michalopoulos, G 1989Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytesCancer Res4933143320PubMed
10.
Zurück zum Zitat Stoker, M, Gherardi, E, Perryman, M, Gray, J 1987Scatter factor is a fibroblast-derived modulator of epithelial cell mobilityNature327239242PubMedCrossRef Stoker, M, Gherardi, E, Perryman, M, Gray, J 1987Scatter factor is a fibroblast-derived modulator of epithelial cell mobilityNature327239242PubMedCrossRef
11.
Zurück zum Zitat Weidner, K, Arakaki, N, Hartmann, G, et al. 1991Evidence for the identity of human scatter factor and human hepatocyte growth factorProc Natl Acad Sci USA8870017005PubMedCrossRef Weidner, K, Arakaki, N, Hartmann, G,  et al. 1991Evidence for the identity of human scatter factor and human hepatocyte growth factorProc Natl Acad Sci USA8870017005PubMedCrossRef
12.
Zurück zum Zitat Naldini, L, Weidner, KM, Vigna, E, et al. 1991Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptorEMBO J1028672878PubMed Naldini, L, Weidner, KM, Vigna, E,  et al. 1991Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptorEMBO J1028672878PubMed
13.
Zurück zum Zitat Zarnegar, R, Michalopoulos, GK 1995The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesisJ Cell Biol12911771180PubMedCrossRef Zarnegar, R, Michalopoulos, GK 1995The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesisJ Cell Biol12911771180PubMedCrossRef
14.
Zurück zum Zitat Matsumoto, K, Nakamura, T 1996Emerging multipotent aspects of hepatocyte growth factorJ Biochem (Tokyo)119591600 Matsumoto, K, Nakamura, T 1996Emerging multipotent aspects of hepatocyte growth factorJ Biochem (Tokyo)119591600
15.
Zurück zum Zitat Bellusci, S, Moens, G, Gaudino, G, et al. 1994Creation of a hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicityOncogene910911099PubMed Bellusci, S, Moens, G, Gaudino, G,  et al. 1994Creation of a hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicityOncogene910911099PubMed
16.
Zurück zum Zitat Rong, S, Segal, S, Anver, M, Resau, JH, Woude, GF 1994Invasiveness and metastasis of NIH3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulationProc Natl Acad Sci USA9147314735PubMedCrossRef Rong, S, Segal, S, Anver, M, Resau, JH, Woude, GF 1994Invasiveness and metastasis of NIH3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulationProc Natl Acad Sci USA9147314735PubMedCrossRef
17.
Zurück zum Zitat Lamszus, K, Jin, L, Fuchs, A, et al. 1997Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pad of nude miceLab Invest76339353PubMed Lamszus, K, Jin, L, Fuchs, A,  et al. 1997Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pad of nude miceLab Invest76339353PubMed
18.
Zurück zum Zitat Nakamura, T, Matsumoto, K, Kiritoshi, A, et al. 1997Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactionsCancer Res5733053313PubMed Nakamura, T, Matsumoto, K, Kiritoshi, A,  et al. 1997Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactionsCancer Res5733053313PubMed
19.
Zurück zum Zitat Abounader, R, Ranganathan, S, Lal, B, et al. 1999Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expressionJ Natl Cancer Inst9115481556PubMedCrossRef Abounader, R, Ranganathan, S, Lal, B,  et al. 1999Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expressionJ Natl Cancer Inst9115481556PubMedCrossRef
20.
Zurück zum Zitat Ronen, D, Alstock, RT, Firon, M, et al. 1999Met-HGF/SF mediates growth arrest and differentiation in T47D breast cancer cellsCell Growth Differ10131140PubMed Ronen, D, Alstock, RT, Firon, M,  et al. 1999Met-HGF/SF mediates growth arrest and differentiation in T47D breast cancer cellsCell Growth Differ10131140PubMed
21.
Zurück zum Zitat Fukuura, T, Miki, C, Inoue, T, Matsumoto, K, Suzuki, H 1998Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinomaBr J Cancer78454459PubMed Fukuura, T, Miki, C, Inoue, T, Matsumoto, K, Suzuki, H 1998Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinomaBr J Cancer78454459PubMed
22.
Zurück zum Zitat Vargas, GA, Hoeflich, A, Jehle, PM 2000Hepatocyte growth factor in renal failure: promise and realityKidney Int5714261435PubMedCrossRef Vargas, GA, Hoeflich, A, Jehle, PM 2000Hepatocyte growth factor in renal failure: promise and realityKidney Int5714261435PubMedCrossRef
23.
Zurück zum Zitat Taniguchi, T, Kitamura, M, Araki, K, et al. 1997Increase in the circulating level of hepatocyte growth factor in gastric cancer patientsBr J Cancer75673677PubMed Taniguchi, T, Kitamura, M, Araki, K,  et al. 1997Increase in the circulating level of hepatocyte growth factor in gastric cancer patientsBr J Cancer75673677PubMed
24.
Zurück zum Zitat Takigawa, N, Segawa, Y, Maeda, Y, Takata, I, Fujimoto, N 1997Serum hepatocyte growth factor/scatter factor levels in small lung cancer patientsLung Cancer17211218PubMedCrossRef Takigawa, N, Segawa, Y, Maeda, Y, Takata, I, Fujimoto, N 1997Serum hepatocyte growth factor/scatter factor levels in small lung cancer patientsLung Cancer17211218PubMedCrossRef
25.
Zurück zum Zitat Toi, M, Taniguchi, T, Ueno, T, et al. 1998Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancerClin Cancer Res4659664PubMed Toi, M, Taniguchi, T, Ueno, T,  et al. 1998Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancerClin Cancer Res4659664PubMed
26.
Zurück zum Zitat Naughton, M, Picus, J, Zhu, X, Catalona, WJ, Vollmer, RT, Humphrey, PA 2001Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancerJ Urol16513251328PubMedCrossRef Naughton, M, Picus, J, Zhu, X, Catalona, WJ, Vollmer, RT, Humphrey, PA 2001Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancerJ Urol16513251328PubMedCrossRef
27.
Zurück zum Zitat Yamagami, H, Moriyama, M, Matsumura, H, et al. 2002Serum concentration of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseasesCancer95824834CrossRef Yamagami, H, Moriyama, M, Matsumura, H,  et al. 2002Serum concentration of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseasesCancer95824834CrossRef
28.
Zurück zum Zitat Alexandrakis, MG, Passam, FH, Sfridaki, A, Kandidaki, E, Roussou, P, Kyriakou, DS 2003Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activityAm J Hematol72229233PubMedCrossRef Alexandrakis, MG, Passam, FH, Sfridaki, A, Kandidaki, E, Roussou, P, Kyriakou, DS 2003Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activityAm J Hematol72229233PubMedCrossRef
29.
Zurück zum Zitat Hsiao, LT, Lin, JT, Yu, IT, et al. 2003High serum hepatocyte growth factor level in patients with non-Hodgkin’s lymphomaEur J Haematol70282289PubMedCrossRef Hsiao, LT, Lin, JT, Yu, IT,  et al. 2003High serum hepatocyte growth factor level in patients with non-Hodgkin’s lymphomaEur J Haematol70282289PubMedCrossRef
30.
Zurück zum Zitat Vesely, D, Astl, J, Lastuvka, P, Matucha, P, Sterzl, I, Betka, J 2004Serum levels of IGF-1, HGF, TGF beta 1, bFGF and VEGF in thyroid gland tumorsPhysiol Res538389PubMed Vesely, D, Astl, J, Lastuvka, P, Matucha, P, Sterzl, I, Betka, J 2004Serum levels of IGF-1, HGF, TGF beta 1, bFGF and VEGF in thyroid gland tumorsPhysiol Res538389PubMed
31.
Zurück zum Zitat Tanaka, K, Miki, C, Wakuda, R, Kobayashi, M, Tonouchi, H, Kusunoki, M 2004Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinomaScand J Gastroenterol39754760PubMedCrossRef Tanaka, K, Miki, C, Wakuda, R, Kobayashi, M, Tonouchi, H, Kusunoki, M 2004Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinomaScand J Gastroenterol39754760PubMedCrossRef
32.
Zurück zum Zitat Kermorgant, S, Cadiot, G, Lewin, MJ, Lehy, T 1996Expression of hepatocyte growth factor and its receptor, C-Met in human digestive tissues and different gastric and colonic cancer cell linesGastroenterol Clin Biol20438445PubMed Kermorgant, S, Cadiot, G, Lewin, MJ, Lehy, T 1996Expression of hepatocyte growth factor and its receptor, C-Met in human digestive tissues and different gastric and colonic cancer cell linesGastroenterol Clin Biol20438445PubMed
33.
Zurück zum Zitat Hu, RH, Lee, PH, Yu, SC, Sheu, JC, Lai, MY 1999Serum hepatocyte growth factor before and after resection for hepatocellular carcinomaHepatogastroenterology4618421847PubMed Hu, RH, Lee, PH, Yu, SC, Sheu, JC, Lai, MY 1999Serum hepatocyte growth factor before and after resection for hepatocellular carcinomaHepatogastroenterology4618421847PubMed
34.
Zurück zum Zitat Bilezikci, B, Haberal, AN, Demirhan, B 2001Hepatocyte growth factor in patients with three different stages of chronic liver disease including hepatocellular carcinoma, cirrhosis and chronic hepatitis: an immunohistochemical studyCan J Gastroenterol15159165PubMed Bilezikci, B, Haberal, AN, Demirhan, B 2001Hepatocyte growth factor in patients with three different stages of chronic liver disease including hepatocellular carcinoma, cirrhosis and chronic hepatitis: an immunohistochemical studyCan J Gastroenterol15159165PubMed
35.
Zurück zum Zitat Otte, JM, Schmitz, F, Kiehne, K, et al. 2000Functional expression of HGF and its receptor in human colorectal cancerDigestion61237246PubMedCrossRef Otte, JM, Schmitz, F, Kiehne, K,  et al. 2000Functional expression of HGF and its receptor in human colorectal cancerDigestion61237246PubMedCrossRef
36.
Zurück zum Zitat Thompson, JA, Grunert, F, Zimmermann, W 1991Carcinoembryonic antigen gene family: molecular biology and clinical perspectivesJ Clin Lab Anal5344366PubMed Thompson, JA, Grunert, F, Zimmermann, W 1991Carcinoembryonic antigen gene family: molecular biology and clinical perspectivesJ Clin Lab Anal5344366PubMed
Metadaten
Titel
Combined Measurement of Hepatocyte Growth Factor and Carcinoembryonic Antigen as a Prognostic Marker for Patients with Dukes A and B Colorectal Cancer: Results of a Five-Year Study
verfasst von
Chikao Miki, M.D.
Yasuhiro Inoue, M.D.
Jun-ichiro Hiro, M.D.
Eiki Ojima, M.D.
Toshimitsu Araki, M.D.
Keiichi Uchida, M.D.
Masato Kusunoki, M.D.
Publikationsdatum
01.11.2006
Erschienen in
Diseases of the Colon & Rectum / Ausgabe 11/2006
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-006-0697-9

Weitere Artikel der Ausgabe 11/2006

Diseases of the Colon & Rectum 11/2006 Zur Ausgabe

Letters to the Editor

The Authors Reply

Colorectal Website Review

Colonoscopy

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.